37 research outputs found
Recommended from our members
Risk of radiation-induced cancers in patients treated with contemporary radiation therapy for early-stage lung cancer
Purpose: In the contemporary management of early-stage lung cancer with RadiationTherapy (RT), there is increased imaging utilization for the diagnosis and treatment and follow-up after completion of treatment. We evaluated whether this increased radiation exposure to patients with early-stage lung cancer that receive stereotactic body radiotherapy (SBRT) significantly increases the risk of radiation-induced carcinogenesis (RIC). Methods: Following IRB approval, one hundred and ninety-six consecutively treated lung cancer patients treated with SBRT were selected for analysis. Information collected included demographics and all ionizing imaging scans one year before SBRT treatment and one year following treatment. These included chest X-rays (CXR), computerized tomography scan (CT scan), positron emission tomography scan (PET-CT scan), bone scan, ventilation-perfusion scan (VQ scan), cone-beam CT scans. In addition to the lung cancer patients, comparative data on ten prostate and breast cancer patients each was collected to get an estimate of the radiation-induced risk (RIC) in other common malignancies. For each patient, the total effective dose (mSv) was calculated by the sum of all effective doses for all scans (1 year before SBRT to 1-year post-SBRT). After calculating the total effective dose, the summed dose was used to calculate the RIC using the RadRat tool. For the study, we decided that a 1% increase in the baseline risk of radiation-induced lung cancer will be considered a significant increase. Results: Among lung cancer patients, there were 87 males (44.4%) and 109 females (55.6%). The median number of Pre-SBRT CXRs (PA/lateral) was 2 (Range: 1-22), the median number of pre-SBRT CT scans was 2 (Range: 1-6), the median number of pre-SBRT PET-CT scans was 1 (Range: 1-4), the median number of Bone Scans or VQ scans pre-SBRT was 1. The median effective exposure dose from all scans was 72mSv (Range: 24-140.36mSv). The median excess lifetime risk (ELR) of developing lung cancer (a chance in 100,000) with a 90% uncertainty range was 57.15. The Excess Future risk (EFR), the risk from 2019 to the end of the expected lifetime of developing cancer (a chance in 100,000), showed a median of EFR mean of 73.75 (Range: 8.45- 416). The total future risk (TFR, a sum of baseline and excess risk) of developing cancer, from 2019 to end of an expected lifetime was 2732.5 (Range: 808-8290), the median of TFR upper bound was 2785.5 (Range: 856-8400) and median of TFR lower bound was 2679.5 (Range: 761- 8183).
At 6 months, survival was 94.7% (144/152), at 1 year, 79% (94/119), at 3 years 32.5% (27/83). At five years, with survival data on 77 patients available, 9 (11.6%) were alive. Regarding the comparison of RIC from imaging before RT for patients with prostate cancer, the median total effective radiation dose from all pre-SBRT and post-SBRT scans was 20mSv (Range: 20-30mSv), and the median of mean ELR for development of RIC prostate cancer was 4.24 (per 100,000). Regarding early-stage breast cancer, the median total effective radiation dose from all pre-RT and post-RT scans was 16.56mSv (Range: 10.52-31.48mSv), and the median of mean ELR for development of RIC was 35.95 (per 100,000). Conclusion: The median excess cancer lifetime radiation-induced cancer risk for the lung cancer cohort was 0.05%, which is significantly less than the 1% risk that was determined to be clinically significant as per our study objective. The survival in this cohort of patients was poor. Enhanced imaging to enhance staging accuracy, safety during SBRT treatment, and adequate follow-up outweigh the RIC risk
Dosimetric differences between cesium-131 and iodine-125 brachytherapy for the treatment of resected brain metastases
Purpose: To compare treatment plans and evaluate dosimetric characteristics of permanent cesium-131 (131Cs) vs. iodine-125 (125I) implants used in brain brachytherapy. Material and methods: Twenty-four patients with 131Cs implants from a prospective phase I/II trial were re-planned with 125I implants. In order to evaluate the volume of brain tissue exposed to radiation therapy (RT), the dose volume histogram was generated for both radioisotopes. To evaluate the dosimetric differences of the two radioisotopes we compared homogeneity (HI) and conformity indices (CI), and dose covering 100% (D100), 90% (D90), 80% (D80), and 50% (D50) of the clinical target volume (CTV). Results: At the 100%, 90%, 80%, and 50% isodose lines, the 131Cs plans exposed less mean volume of brain tissue than the 125I plans (p \u3c 0.001). The D100, D90, D80, and D50 were smaller for 131Cs (p \u3c 0.001). The HI and CI for 131Cs vs. 125I were 19.71 vs. 29.04 and 1.31 vs. 1.92, respectively (p \u3c 0.001). Conclusions: Compared to 125I, 131Cs exposed smaller volumes of brain tissue to equivalent doses of radiation and delivered lower radiation doses to equivalent volumes of the CTV. 131Cs exhibited a higher HI, indicating increased uniformity of doses within the CTV. Lastly, 131Cs presented a CI closer to 1, indicating that the total volume receiving the prescription dose was closer to the desired CTV volume. These results suggest that 131Cs is dosimetrically superior to 125I and may explain the reason for the 0% incidence of radiation necrosis (RN) in our previously published prospective study using 131Cs
Feasibility and safety of GliaSite brachytherapy in treatment of CNS tumors following neurosurgical resection
Purpose: To investigate feasibility and safety of GliaSite
brachytherapy for treatment of central nervous system (CNS) tumors
following neurosurgical resection. We report mature results of
long-term follow-up, outcomes and toxicity. Materials and Methods: In
the period from 2004 to 2007, 10 consecutive adult patients with
recurrent, newly diagnosed, and metastatic brain malignancies underwent
GliaSite brachytherapy following maximally safe neurosurgical
resection. While 6/10 (60%) patients were treated for recurrence,
having previously been treated with external beam radiotherapy (EBRT),
4/10 (40%) received radiotherapy (RT) for the first time. A median dose
of 52.0 Gy (range, 45.0 - 60.0 Gy) was prescribed to 0.5 cm - 1.0 cm
from the balloon surface. Radiation Therapy Oncology Group (RTOG)
criteria were used to assess toxicities associated with this technique.
Follow-up was assessed with MRI scans and was available on all enrolled
patients. Results: Median follow-up was 38 months (range, 18 - 57
months). Mean size of GliaSite balloon was 3.4 cm (range, 2.0 - 4.0
cm). Median survival was 14.0 months for the entire cohort after the
treatment. The 17.6 and 16.0 months average survival for newly
diagnosed and recurrent high grade gliomas (HGG), respectively,
translated into a three-month improvement in survival in patients with
newly diagnosed HGG compared to historical controls (P = 0.033). There
were no RTOG grades 3 or 4 acute or late toxicities. Follow-up magnetic
resonance imaging (MRI) imaging did not identify radiation necrosis.
Conclusions: Our data indicate that treatment with GliaSite
brachytherapy is feasible, safe and renders acceptable local control,
acute and long-term toxicities. We are embarking on testing larger
numbers of patients with this treatment modality
Recommended from our members
Multi-Institutional Study Validates Safety of Intraoperative Cesium-131 Brachytherapy for Treatment of Recurrent Head and Neck Cancer
Introduction: Surgery is the primary treatment for resectable, non-metastatic recurrent head and neck squamous cell carcinoma (HNSCC). We explore the safety and oncologic benefit of intraoperative Cesium-131 (Cs-131) brachytherapy combined with salvage local and/or regional surgical resection.
Methods and materials: Findings were reported from a single arm multi-institutional prospective phase 1/2 trial involving surgery plus Cs-131 (surgery + Cs-131) treatment. The results of two retrospective cohorts-surgery alone and surgery plus intensity modulated radiation therapy (surgery + ReIMRT)-were also described. Included patients had recurrent HNSCC and radiation history. Safety, tumor re-occurrence, and survival were evaluated.
Results: Forty-nine patients were enrolled in the surgery + Cs-131 prospective study. Grade 1 to 3 adverse events (AEs) occurred in 18 patients (37%), and grade 4 AEs occurred in 2 patients. Postoperative percutaneous endoscopic gastrostomy (PEG) tubes were needed in 10 surgery + Cs-131 patients (20%), and wound and vascular complications were observed in 12 patients (24%). No cases of osteoradionecrosis were reported in the surgery + Cs-131 cohort. We found a 49% 2-year disease-free survival at the site of treatment with a substantial number of patients (31%) developing metastatic disease, which led to a 31% overall survival at 5 years.
Conclusions: Among patients with local/regional recurrent HNSCC status-post radiation, surgery + Cs-131 demonstrated acceptable safety with compelling oncologic outcomes, as compared to historic control cohorts.
Clinical trial registration: ClinicalTrials.gov, identifiers NCT02794675 and NCT02467738
Pure seminoma in the setting of androgen insensitivity syndrome treated with surgical resection and para-aortic radiation: A case report and review of literature
Complete androgen insensitivity is a rare X-linked disorder
characterized by a female phenotype in a chromosomally male individual.
Malignant transformation of the un-descended testis is a rare phenomena
compared to other inter-sex syndromes. This is a case of a 32-year-old
female who was diagnosed with androgen insensitivity and presented to
the emergency room with pelvic pain. Later the pelvic pain was found to
be due to testicular masses, one of which was pure seminoma. We
reviewed the literature emphasizing the biochemical and endocrinologic
abnormalities leading to the syndrome, as well as the potential for
malignant changes of the un-descended testes, diagnosis, and
therapeutic management. We discuss the importance of early diagnosis
and the consequence associated with misdiagnosis
Addition of Surgery After Radiation Significantly Improves Survival in Stage IIIB Non-small Cell Lung Cancer: A Population-Based Analysis.
Unresectable Retiform Hemangioendothelioma Treated with External Beam Radiation Therapy and Chemotherapy: A Case Report and Review of the Literature
Retiform hemangioendothelioma (RH) is an infrequently encountered vascular neoplasm of intermediate or borderline malignancy. Treatment of RH is controversial. We present a case of a 44-year-old Asian male presenting with an unresectable RH of the pelvis. The patient was treated with concurrent low-dose Cisplatin and External beam Radiation (4140cGy in 180cGy per fraction). This is the first report of a clinical complete response and a long-term local control of this rare tumor. This has significant clinical implication, since it gives the first evidence of treatment of this rare tumor using concurrent low-dose chemotherapy and radiation
Pure seminoma in the setting of androgen insensitivity syndrome treated with surgical resection and para-aortic radiation: A case report and review of literature
Complete androgen insensitivity is a rare X-linked disorder
characterized by a female phenotype in a chromosomally male individual.
Malignant transformation of the un-descended testis is a rare phenomena
compared to other inter-sex syndromes. This is a case of a 32-year-old
female who was diagnosed with androgen insensitivity and presented to
the emergency room with pelvic pain. Later the pelvic pain was found to
be due to testicular masses, one of which was pure seminoma. We
reviewed the literature emphasizing the biochemical and endocrinologic
abnormalities leading to the syndrome, as well as the potential for
malignant changes of the un-descended testes, diagnosis, and
therapeutic management. We discuss the importance of early diagnosis
and the consequence associated with misdiagnosis